These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 24764221

  • 21. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.
    Muñoz-Rojas MV, Horovitz DD, Jardim LB, Raymundo M, Llerena JC, de Magalhães Tde S, Vieira TA, Costa R, Kakkis E, Giugliani R.
    Mol Genet Metab; 2010 Apr; 99(4):346-50. PubMed ID: 20036175
    [Abstract] [Full Text] [Related]

  • 22. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB.
    Drugs R D; 2005 Apr; 6(5):312-5. PubMed ID: 16128602
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
    Muenzer J.
    Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
    [Abstract] [Full Text] [Related]

  • 25. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy.
    Braunlin E, Rosenfeld H, Kampmann C, Johnson J, Beck M, Giugliani R, Guffon N, Ketteridge D, Sá Miranda CM, Scarpa M, Schwartz IV, Leão Teles E, Wraith JE, Barrios P, Dias da Silva E, Kurio G, Richardson M, Gildengorin G, Hopwood JJ, Imperiale M, Schatz A, Decker C, Harmatz P, MPS VI Study Group.
    J Inherit Metab Dis; 2013 Mar; 36(2):385-94. PubMed ID: 22669363
    [Abstract] [Full Text] [Related]

  • 26. Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation.
    Sohn YB, Park SW, Kim SH, Cho SY, Ji ST, Kwon EK, Han SJ, Oh SJ, Park YJ, Ko AR, Paik KH, Lee J, Lee DH, Jin DK.
    Am J Med Genet A; 2012 May; 158A(5):1158-63. PubMed ID: 22495825
    [Abstract] [Full Text] [Related]

  • 27. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.
    Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, Eto Y, Gold JI, Jester A, Jones SA, Karsli C, Mackenzie W, Marinho DR, McFadyen A, McGill J, Mitchell JJ, Muenzer J, Okuyama T, Orchard PJ, Stevens B, Thomas S, Walker R, Wynn R, Giugliani R, Harmatz P, Hendriksz C, Scarpa M, MPS Consensus Programme Steering Committee, MPS Consensus Programme Co-Chairs.
    Orphanet J Rare Dis; 2019 May 29; 14(1):118. PubMed ID: 31142378
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.
    Brands MM, Hoogeveen-Westerveld M, Kroos MA, Nobel W, Ruijter GJ, Özkan L, Plug I, Grinberg D, Vilageliu L, Halley DJ, van der Ploeg AT, Reuser AJ.
    Orphanet J Rare Dis; 2013 Apr 04; 8():51. PubMed ID: 23557332
    [Abstract] [Full Text] [Related]

  • 30. Enzyme replacement therapy for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): experience in Hong Kong.
    But WM, Wong MY, Chow JC, Chan WK, Ko WT, Wu SP, Wong ML, Miu TY, Tse WY, Hung WW, Fan TW, Shek CC.
    Hong Kong Med J; 2011 Aug 04; 17(4):317-24. PubMed ID: 21813902
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Long-term cognitive follow-up in children treated for Maroteaux-Lamy syndrome.
    Ebbink BJ, Brands MM, van den Hout JM, Lequin MH, Coebergh van den Braak RR, van de Weitgraven RL, Plug I, Aarsen FK, van der Ploeg AT.
    J Inherit Metab Dis; 2016 Mar 04; 39(2):285-92. PubMed ID: 26450354
    [Abstract] [Full Text] [Related]

  • 36. Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
    McDonald A, Steiner R, Kuehl K, Turbeville S.
    J Pediatr Rehabil Med; 2010 Mar 04; 3(2):119-27. PubMed ID: 21791839
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy].
    Politei J, Schenone A, Blanco M, Szlago M.
    Arch Argent Pediatr; 2014 Jun 04; 112(3):258-62. PubMed ID: 24862809
    [Abstract] [Full Text] [Related]

  • 39. Abnormal granulation of blood granulocytes in mucopolysaccharidosis VI-a case report.
    Krishnagiri C, Ajanahalli RR, Kashyap S, Anegundi R, Boranaik L.
    Ann Diagn Pathol; 2013 Feb 04; 17(1):137-9. PubMed ID: 22056033
    [Abstract] [Full Text] [Related]

  • 40. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up.
    Furujo M, Kosuga M, Okuyama T.
    Mol Genet Metab Rep; 2017 Dec 04; 13():69-75. PubMed ID: 28983456
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.